Guardant Health (NASDAQ:GH) Insider Sells $977,865.39 in Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 8,571 shares of the firm’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the completion of the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at approximately $2,394,749.10. This trade represents a 28.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Guardant Health Trading Up 1.3%

Shares of NASDAQ GH traded up $1.53 during trading hours on Thursday, hitting $117.28. 3,002,462 shares of the company traded hands, compared to its average volume of 2,245,633. The company’s 50 day moving average price is $104.37 and its 200 day moving average price is $76.71. Guardant Health, Inc. has a 12 month low of $34.88 and a 12 month high of $120.74. The stock has a market capitalization of $14.78 billion, a price-to-earnings ratio of -36.54 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. During the same quarter in the prior year, the firm posted ($0.88) EPS. Guardant Health’s revenue was up 38.5% compared to the same quarter last year. Equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GH. AQR Capital Management LLC grew its holdings in shares of Guardant Health by 56.5% during the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after buying an additional 25,831 shares during the last quarter. Empowered Funds LLC purchased a new stake in Guardant Health during the 1st quarter valued at about $274,000. Signaturefd LLC increased its holdings in shares of Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after purchasing an additional 213 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of Guardant Health by 277.8% in the second quarter. Janney Montgomery Scott LLC now owns 20,574 shares of the company’s stock valued at $1,071,000 after purchasing an additional 15,128 shares during the period. Finally, Trivium Point Advisory LLC purchased a new position in shares of Guardant Health in the second quarter worth about $249,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on GH shares. Morgan Stanley upped their price target on shares of Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. BTIG Research upped their target price on Guardant Health from $100.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, December 12th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Leerink Partners upped their price objective on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Stifel Nicolaus lifted their target price on Guardant Health from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Twenty-one research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and a consensus target price of $102.81.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.